Yantai Dongcheng Pharmaceutical Co Ltd (002675) - Total Liabilities
Based on the latest financial reports, Yantai Dongcheng Pharmaceutical Co Ltd (002675) has total liabilities worth CN¥3.84 Billion CNY (≈ $561.90 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002675 cash flow conversion to assess how effectively this company generates cash.
Yantai Dongcheng Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Yantai Dongcheng Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Yantai Dongcheng Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Yantai Dongcheng Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yantai Dongcheng Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ELECTROLUX B ADR/2 SK 5
F:ELXA
|
Germany | €105.92 Billion |
|
Herbalife Nutrition Ltd
NYSE:HLF
|
USA | $3.30 Billion |
|
Mitra Keluarga Karyasehat Tbk PT
JK:MIKA
|
Indonesia | Rp1.58 Trillion |
|
Lonking Holdings Limited
F:C9IB
|
Germany | €5.70 Billion |
|
Pexa Group Ltd
AU:PXA
|
Australia | AU$540.95 Million |
|
BW Energy Ltd
OL:BWE
|
Norway | Nkr1.48 Billion |
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
USA | $170.73 Million |
|
BlackRock Capital Allocation Trust
NYSE:BCAT
|
USA | $224.02 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Yantai Dongcheng Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002675 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yantai Dongcheng Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yantai Dongcheng Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total liabilities of Yantai Dongcheng Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.26 Billion ≈ $477.51 Million |
+21.46% |
| 2023-12-31 | CN¥2.69 Billion ≈ $393.15 Million |
-7.18% |
| 2022-12-31 | CN¥2.89 Billion ≈ $423.57 Million |
+9.96% |
| 2021-12-31 | CN¥2.63 Billion ≈ $385.22 Million |
+8.44% |
| 2020-12-31 | CN¥2.43 Billion ≈ $355.23 Million |
-3.52% |
| 2019-12-31 | CN¥2.52 Billion ≈ $368.18 Million |
+6.76% |
| 2018-12-31 | CN¥2.36 Billion ≈ $344.86 Million |
+18.76% |
| 2017-12-31 | CN¥1.98 Billion ≈ $290.38 Million |
+67.61% |
| 2016-12-31 | CN¥1.18 Billion ≈ $173.25 Million |
+279.54% |
| 2015-12-31 | CN¥311.94 Million ≈ $45.65 Million |
+49.21% |
| 2014-12-31 | CN¥209.06 Million ≈ $30.59 Million |
+64.39% |
| 2013-12-31 | CN¥127.18 Million ≈ $18.61 Million |
+74.59% |
| 2012-12-31 | CN¥72.84 Million ≈ $10.66 Million |
-50.38% |
| 2011-12-31 | CN¥146.82 Million ≈ $21.48 Million |
-12.68% |
| 2010-12-31 | CN¥168.14 Million ≈ $24.60 Million |
+32.88% |
| 2009-12-31 | CN¥126.53 Million ≈ $18.52 Million |
+9.32% |
| 2008-12-31 | CN¥115.74 Million ≈ $16.94 Million |
-- |
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluro… Read more